The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
R. Dummer
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
J. Rinderknecht
No relevant relationships to disclose
S. M. Goldinger
No relevant relationships to disclose
I. Wagner
No relevant relationships to disclose
L. Mitchell
No relevant relationships to disclose
M. L. Veronese
Employment or Leadership Position - Roche
S. Nick
Employment or Leadership Position - Roche
Stock Ownership - Roche
P. Hilfiker
No relevant relationships to disclose
S. Gobbi
No relevant relationships to disclose